Engflag

Paramegal

Quick links to important sections

Paramegal

Paramegal_IT

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Pain Reliever

Treatment option: Arthralgia, Period Pain, Backache, Pain, Sore Throat, Earache, Headache, Influenza, Toothache, Fever

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paramegal

Property Description
Active Ingredient Acetaminophen (Paracetamol, APAP)
Pharmacological Class Analgesic (Pain Reliever) and Antipyretic (Fever Reducer)
Common Forms Tablet, capsule, liquid suspension, suppository
Origin Synthetic compound

What is Paramegal and Its Pharmacological Class?

Paramegal is a recognized brand of a widely utilized synthetic medicinal preparation classified primarily as a non-opioid analgesic and an antipyretic. Its core active component is Acetaminophen, an international nonproprietary name (INN) also globally known as Paracetamol. This medication is noted for its efficacy in managing general mild to moderate discomfort and reducing elevated body temperature, a function utilized for decades across medical institutions.

As a foundational treatment, Paramegal is typically available as an over-the-counter (OTC) medicine, making it readily accessible for acute symptomatic relief. The active ingredient, Paracetamol, is widely categorized as an essential medicine, reflecting its status in healthcare systems.

Composition, Forms, and General Therapeutic Purpose

The formulation of Paramegal is generally that of a single-ingredient product, containing only Acetaminophen as the therapeutic agent alongside standard, inert pharmaceutical excipients required for stability. This composition simplifies its pharmacological profile.

The drug is manufactured in a variety of dosage forms to accommodate diverse administration needs, including standard solid oral preparations (tablets, capsules) and specialized liquid preparations (syrups and suspensions). Paramegal often focuses its specialized forms toward pediatric patient groups, providing forms that support precise administration for children. This flexibility ensures that the primary therapeutic goal—the provision of effective pain relief and fever reduction—remains accessible through the oral, rectal, or intravenous route of administration, even when a patient is unable to swallow medication.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Paramegal?

Possible Side Effects and Safety Information

The official safety profile for Paramegal, which contains Acetaminophen (Paracetamol), is structured around officially documented adverse reactions and specific constraints defined in regulatory documents.

Serious Adverse Reactions and Safety Constraints

The primary serious safety concern highlighted in regulatory labeling is the risk of acute liver failure, which has been associated with exceeding recommended doses and may result in the need for a liver transplant or be fatal. Additionally, rare but severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), are formally documented safety hazards.

  • Contraindications: Use is formally restricted and contraindicated for individuals with known hypersensitivity to Acetaminophen or with severe active liver disease.
  • Population Cautions: Official warnings advise caution for patients with severe renal impairment, hepatic impairment, alcoholism, or chronic malnutrition.

Common Adverse Reactions and System Groupings

Adverse effects are categorized by the body system affected (System Organ Class, or SOC).

System Organ Class Examples of Documented Reactions
Hepatobiliary Disorders Hepatic injury, elevated liver enzymes
Gastrointestinal Disorders Nausea, vomiting, constipation
Nervous System Disorders Headache, insomnia
Skin Disorders Rash, pruritus (itching)

Reactions such as nausea, vomiting, and headache are classified as Common effects in regulatory summaries derived from clinical trial data. Chronic regular use is explicitly documented as potentially enhancing the anticoagulant effect of warfarin-type medications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Paramegal (Acetaminophen) overdose emphasizes a time-dependent, life-threatening risk to the hepatic system. The primary severe outcome is documented as acute liver failure (ALF) and hepatic necrosis, which may progress to death.

Documented Manifestations and Systems

Initial manifestations may be non-specific, including nausea, vomiting, paleness, and malaise, which can evolve into signs of severe liver damage, such as jaundice and right upper quadrant pain. Laboratory abnormalities include elevated liver enzyme levels. Physiological systems affected include the hepatic, renal, and central nervous systems (e.g., seizures, cerebral edema).

Mandatory Emergency Action

Seeking immediate medical attention is mandatory for any suspected overdose or ingestion of a potentially toxic amount, even if the individual remains asymptomatic. This action is critical because the documented antidote, N-acetylcysteine (NAC), must be administered within a time-critical therapeutic window to prevent or lessen hepatic injury.

Overdose Considerations

Susceptibility to toxicity is documented as increased in patients with chronic alcohol consumption and malnutrition. Regulatory protocols require continuous hospital monitoring, laboratory testing, and management based on ingestion type (e.g., single acute versus repeated supratherapeutic ingestion).

Therapeutic Uses of Paramegal

What Paramegal Treats: Main Uses and Benefits

Paramegal is commonly used to help with symptoms related to physical discomfort. This medication is categorized as relevant for easing this type of discomfort and contributes to improved comfort.

This agent may assist with managing symptoms related to systemic imbalance, such as fever, and is applied in addressing such symptoms. It is commonly used across conditions presenting with systemic or localized discomfort, including headaches, muscle aches, toothaches, minor arthritis pain, and symptoms associated with the common cold or flu.

The use of this medication supports general well-being during symptomatic phases. It assists with maintaining functional stability when symptoms interfere with daily functioning. This product is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Symptoms related to physical discomfort (pain) and systemic imbalance (fever)

Eligibility and Restrictions for Use

The eligibility for Paramegal (Acetaminophen/Paracetamol) use is defined by official regulatory labeling, primarily based on the user's physiological status and allergy history.

Populations Contraindicated (Must Not Use)

  • Individuals with severe hepatic impairment or severe active liver disease are formally excluded from use.
  • Patients with a known hypersensitivity or allergy to the active ingredient (acetaminophen) or any excipients in the formulation must not use this medicine.

Populations Requiring Conditional Use

  • Liver Risk: Caution is required for individuals with non-severe hepatic impairment, chronic alcoholism, chronic malnutrition, or severe hypovolemia.
  • Renal Impairment: Use requires caution in patients with severe renal impairment (creatinine clearance le 30 mL/min), as this may necessitate adjusted administration timing.

Age-Group Eligibility

  • Adults and Adolescents are generally eligible for standard labeled use.
  • Pediatric use is established in children two years of age and older. For certain formulations, effectiveness has not been established in children younger than two years.
  • Older Adults (Geriatric) show no significant differences in effectiveness compared to younger subjects in clinical studies.

Pregnancy and Lactation Status

  • Pregnancy: The medicine is generally considered acceptable when clinically necessary, but use should be limited to the lowest effective dose for the shortest possible duration.
  • Lactation: The medicine is considered suitable for use in breastfeeding mothers at the usual therapeutic doses.

What should I know about interactions with other medicines?

Paramegal Interactions with other medicines and products

Co-administration with other medicinal products containing Acetaminophen is formally contraindicated in regulatory documents to prevent accidental overdose and the resulting risk of acute liver failure. The product is also contraindicated in individuals with severe active liver disease.

Pharmacokinetic interactions are centered on altered metabolism and clearance. Substances that act as liver enzyme inducers (e.g., Carbamazepine, Phenytoin, Rifampicin) are documented to increase the drug’s hepatotoxic potential. Probenecid significantly reduces Paramegal's plasma clearance by inhibiting its conjugation, an interaction that may warrant consideration for dose adjustment. The speed of absorption is increased by Metoclopramide and Domperidone, while it is reduced by Colestyramine, which requires that co-administration be separated by at least one hour.

A clinically significant pharmacodynamic interaction exists with Warfarin and other Coumarins. Regular, high-dose use of Paramegal is documented to enhance the anticoagulant effect, potentially leading to an increase in INR values. Chronic co-administration with Zidovudine has been associated with neutropenia. Furthermore, chronic, excessive consumption of Alcohol is noted to increase the risk of hepatotoxicity. For patients with severe renal impairment, regulatory labeling notes that longer dosing intervals may be appropriate due to the risk of metabolite accumulation.

Mechanism of Action

Paramegal, a moderately lipophilic compound, crosses the blood-brain barrier (BBB) to exert its principal actions within the central nervous system (CNS). Its mechanism involves multiple targets and pathways. A primary action is the functional inhibition of cyclooxygenase (COX) enzymes, particularly a central splice variant of COX-1 or COX-2, by acting as a reducing co-substrate at the peroxidase site. This interaction prevents the formation of a critical tyrosine radical essential for the cyclooxygenase activity, thereby reducing the intracellular synthesis of prostaglandin E2 (PGE2) within the brain and spinal cord. --- Another key pathway involves the drug's metabolism to N-arachidonoylphenolamine (AM404), which acts as an agonist at the transient receptor potential vanilloid-1 (TRPV1) receptors and an indirect agonist at the cannabinoid type 1 (CB1) receptors. These central interactions modulate the descending inhibitory serotonergic pathways. The combined modulation of PGE2 synthesis and TRPV1/CB1 signaling culminates in a systemic suppression of central thermal regulation and nociceptive transmission.

Dosage and Administration Information

How to Use Paramegal: Standardized Administration Guidelines

This section defines the standardized usage parameters for Paramegal (Acetaminophen), focusing on administration methods, dosing parameters, and procedural conditions.

Administration Scope

Property Standard Instruction/Constraint
Route of administration Administration is documented for the Oral (tablet, liquid), Rectal (suppository), and Intravenous (IV) injection routes.
Dosing schedule The Standard Adult Single Dose ranges from 325 mg up to 1,000 mg. The Maximum Daily Dose is limited to 4,000 mg (4 grams) in 24 hours across all sources of acetaminophen.
Frequency and Timing Dosing is typically applied as needed (PRN), with a minimum interval of 4 to 6 hours between repeated doses.
Preparation and Intake Oral forms are compatible with or without food. Liquid suspensions require shaking well before use and are measured using a dedicated device for accuracy. Intravenous forms are administered in a supervised setting as a 15-minute infusion.
Population Rules Pediatric dosing is determined by weight-based calculations. The maximum daily dose is adjusted for individuals with underlying hepatic impairment, as specified in product labeling.
Procedural Conditions Extended-release tablets are designed to be swallowed whole and are not crushed or chewed. OTC use is generally limited to a short duration, typically no more than 10 days for pain or 3 days for fever.

Connection to the Overall Use Protocol

Standard guidelines outline the maximum daily exposure to the medication and define the appropriate time intervals between doses. This structured approach, which includes specific parameters for administration route, preparation, and dose adjustment in certain populations, describes how the product is utilized across clinical and non-clinical settings.

Recent Clinical Evidence

Paramegal: Recent Clinical Evidence

Evidence for Use in Pain Relief (Analgesia)

The research landscape concerning Paramegal's use in research exploring outcomes related to physical discomfort is built upon short-term, acute Randomized Controlled Trials (RCTs). These studies examine short-term changes in populations, including adults and adolescents experiencing acute pain. Research explores measures like Pain Intensity scores and the Time to onset of patient-reported outcomes describing perceived discomfort. Findings describe measured patterns when comparing the substance to an inactive substance (placebo). However, the results apply only to the populations studied, and data for certain specific chronic pain conditions or complex types of discomfort remain insufficient.

Evidence for Use in Fever Reduction (Antipyresis)

Paramegal was studied for its use in research exploring outcomes related to systemic or functional imbalance, such as elevated body temperature. Controlled clinical trials monitored objective metrics like Core Body Temperature and the documented Time to defervescence (resolution of fever) across all age ranges. Research describes how symptoms evolved in pediatric and adult populations. Findings were mixed when evaluating patient-centered outcomes in critically ill patient populations (e.g., sepsis), indicating that certainty remains low in these specialized scenarios.

Research Gaps and Special Populations

Research has primarily focused on outcomes describing episodic or acute changes. Therefore, long-term effects are not fully established, and there is limited information regarding sustained changes following extended administration. Paramegal was evaluated in pediatric patients, but data for the youngest patient groups often rely on studies assessing pharmacokinetic profiles rather than large-scale efficacy trials. Comparative evidence is lacking in some areas, and the primary focus on short-term relief means that long-term functional stability is not fully characterized.

Frequently Asked Questions (FAQ)

Common questions about Paramegal (FAQ)

Q: What is Paramegal used for?

Paramegal is approved by regulatory bodies for the management of chronic, non-cancer pain that has not responded adequately to other treatment approaches. Its uses are specified on the official product label.

Q: How should I take Paramegal?

Specific instructions on how to take this medication, including frequency and dose, should be provided by a healthcare professional. Always follow the administration directions on your prescription label.

Q: What should I do if I miss a dose of Paramegal?

If a dose is missed, a healthcare provider should be consulted for specific guidance on when to take the next dose. Do not take a double dose to make up for a missed one.

Q: Are there side effects associated with Paramegal?

As with most medications, Paramegal may be associated with side effects. Common effects are listed in the official prescribing information, which may include mild drowsiness or gastrointestinal upset. It is important to discuss any concerns or severe reactions with a healthcare professional.

How should Paramegal be stored and disposed of?

How to Store and Dispose of Paramegal

The storage and disposal of Paramegal (Acetaminophen/Paracetamol) must comply strictly with official regulatory requirements to ensure product integrity and public safety.

Storage Conditions

Paramegal must be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat, cold, and humidity and should remain in the original container. To prevent accidental poisoning, a mandatory instruction on all labels requires the medicine to be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine should preferably be disposed of through an authorized drug take-back program. If this option is not available, the medicine should be mixed with an undesirable substance, such as coffee grounds or dirt, sealed in a bag, and then placed in the household trash. The regulatory guidance instructs users not to flush the medicine down the toilet or pour it down a sink drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCzech Republic

Equivalent of Paramegal found in:

A-Z Index: